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I. INTRODUCTION 
I.1. Mitochondrial respiration and adaptive biogenesis – the role of PGC-1α 
Mitochondria are membrane-bound intracellular organelles evolutionary originating 
from the endosymbiosis of an ancient aerobic alpha-proteobacterium with an early eukaryotic 
host cell [1]. Harboring their own maternally inherited, double-stranded, circular genome 
(mtDNA), supplemented by the presence of several ancillary, structural and regulatory proteins 
encoded by the nuclear DNA (nDNA), mitochondria host a number of molecular processes 
essential for cellular life, development, aging, and death. These include the production of 
biologically utilizable energy through the joint function of respiratory complexes I–V within 
the electron transport chain (ETC) in processes involving terminal oxidation and oxidative 
phosphorylation (OXPHOS), the adaptive thermogenesis via the uncoupling of energy 
production, as well as the regulation of cellular calcium homeostasis, cell-cycle, and 
programmed cell death. Mitochondria are dynamic organelles capable of undergoing fission in 
a process in which mitochondria grow and divide in response to an increased energy demand. 
This process is often referred to as mitochondrial biogenesis. In addition, mitochondria are also 
prone to constant fusion with each other resulting in the mixture (and possibly recombination) 
of normal and potentially mutated genomes (‘heteroplasmy’), which, on the one hand, can 
protect mitochondria and their host cells from the potentially deleterious effects of mtDNA 
mutations, and on the other hand, somewhat counterbalances the limited possibility of genomic 
recombination resulting from the uniparental inheritance. 
The role of PGC-1α in adaptive respiration and mitochondrial biogenesis 
In multicellular organisms, the ability to adaptively regulate and activate mitochondrial 
biogenesis and functions in response to a variety of conditions is essential to maintain energetic 
homeostasis and cellular viability. Several lines of evidence obtained in the past decade suggest 
that peroxisome proliferator-activated receptor-gamma (PPARγ) coactivator 1-alpha (PGC-
1α), a nuclear-encoded coactivator of a wide range of transcriptional factors, plays a key role 
in the transcriptional cascade of such adaptive processes [2]. PGC-1α-mediated coactivation of 
genes such as nuclear respiratory factor 1 and 2 (NRF-1 and -2), PPARs, estrogen-related 
receptors (ERRs), and myocyte-specific enhancer factor 2C (MEF2C) leads to an increased 
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expression of a spectrum of proteins involved in mitochondrial transcription, replication, as 
well as the import and assembly of a number of nuclear-encoded respiratory complex subunits; 
furthermore, it boosts OXPHOS and thermoregulation in a tissue-dependent manner, enhances 
gluconeogenesis and fatty acid oxidation [3], and increases the defense against oxidative stress 
[4] (Figure 1). The inducing effect of physical exercise (mediated by calcineurin A-linked 
MEF2 activity, calcium/calmodulin-dependent protein kinase IV (CaMKIV)-linked cyclic 
AMP (cAMP) response element-binding protein (CREB) activity, and the p38 mitogen-
activated protein kinase (MAPK)-linked activating transcription factor 2 (ATF-2) activity), as 
well as cold exposure and starvation (mediated by catecholamine- and glucagon-induced cAMP 
elevation and a subsequent phosphorylation and activation of CREB by protein kinase A 
(PKA)) on PGC-1α expression is well-documented [3]. Furthermore, energy deprivation 
through a high AMP/ATP ratio leads to an increased AMP-activated protein kinase (AMPK) 
activity and a subsequent phosphorylation of PGC-1α protein, priming PGC-1α for 
deacetylation and thereby activation by silent information regulator 2 homolog 1 (Sirt-1) [5, 6], 
the expression of which is also increased in conditions with energy shortage, i.e., starvation or 
exercise, in response to a high NAD+/NADH ratio [7]. These posttranslational modifications 
on PGC-1α play pivotal roles in adaptive mitochondrial biogenesis. The roles of impaired 
mitochondrial function and more recently a decreased function of the PGC-1α cascade in the 
pathogenesis of degenerative central nervous system (CNS) disorders are of extensive research 
interest. 
I.2. Mitochondrial dysfunction, free radicals, and cell death – regulation by PGC-1α 
Under physiological conditions, the efficiency of reducing of oxygen during terminal 
oxidation is approximately 97–99%, while 1–3% undergo incomplete reduction to superoxide 
(O2
–•), a highly reactive free radical. O2
–• can be transformed into hydrogen peroxide (H2O2) 
both spontaneously and through a reaction catalyzed by mitochondrial manganese superoxide 
dismutase (Mn-SOD) in the matrix. H2O2 normally undergoes degradation by glutathione 
peroxidase (GPX) and catalase (CAT) enzymes, yielding water. 
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Figure 1. The PGC-1α cascade. Transcriptional upregulation or posttranslational activation of 
PGC-1α due to fasting, physical exercise, cold exposure, or pharmacological manipulations 
lead to the transcriptional activation several nuclear-encoded proteins involved in 
mitochondrial functioning at multiple levels, including mitochondrial biogenesis, adaptive 
metabolism, antioxidant responses, and proper ETC assembly/import. Adapted from Szalárdy 
et al., 2015 [2]. 
In case of an impaired function of the mitochondrial ETC, leakage of excess electrons 
from complex I and III leads to a higher amount of O2
–• and subsequent H2O2 production, which 
when exceeding the degradative capacity of the mitochondria can be transformed into the 
extremely toxic hydroxyl radical (HO•), through reaction with transition metals (Fe2+ and Cu2+; 
Fenton reaction). HO• in turn can react with nucleic acids and phospholipids, yielding the 
formation of further toxic radicals and consequent severe functional impairments of the affected 
macromolecules. In addition, O2
–• can also react with nitric oxide (NO•), yielding the highly 
toxic peroxynitrite anion (ONOO–), which can evoke injury to proteins via nitration and 
nitrosylation. These toxic radicals are known as reactive oxygen species (ROS) and reactive 
nitrogen species (RNS), and their damaging effects on macromolecules are referred to as 
oxidative and nitrative/nitrosative stress, respectively. 
With mitochondrial ETC being the main source of ROS and RNS production, 
macromolecular components of the mitochondria are extremely exposed to injury due to 
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oxidative/nitrative/nitrosative stress. The injury to mitochondrial respiratory complex subunits 
has two main consequences: 1) it leads to decreased energy production due to impaired 
OXPHOS; 2) it decreases the efficacy of terminal oxidation, which results in an increased 
production of ROS/RNS, generating a vicious circle. 
The proximity to the main source of free radical production and the relatively high 
proportion of coding sequences render the mitochondrial genome particularly sensitive to 
ROS/RNS-mediated injury [8]. Indeed, the mutation rate of mtDNA relative to nDNA is 
approximately 10:1 [9]. Defensive processes of the mitochondria to counteract excessive free 
radical production involve low molecular weight antioxidants, an enzymatic redox apparatus to 
clear ROS/RNS (e.g., SOD, CAT, GPX, and peroxiredoxin), as well as an nDNA-encoded 
repair machinery. Notably, the ability to cope with oxidative/nitrative/nitrosative stress declines 
with aging [10]; therefore, the rate of mtDNA mutations further increase in the elderly [11]. 
Of note, excessive ROS and RNS accumulation within the mitochondria can trigger the 
opening of mitochondrial permeability transition pores (mtPTP), which, on the one hand, 
decreases the mitochondrial membrane potential further aggravating the initial OXPHOS 
impairment, and, on the other hand, leads to the release of proapoptotic factors (including 
apoptosis-inducing factor (AIF), procaspase-9, and cytochrome c) from the intermembrane 
space to the cytosol. This is, in severe cases, followed by cellular death, which can be either 
apoptotic or necrotic, depending on the severity of the initial insult and subsequent energy 
deprivation [12]. Furthermore, mitochondrial energy deprivation leads to an overactivation of 
extrasynaptic N-methyl-D-aspartate-sensitive (NMDA) glutamate receptors, which by resulting 
in an excessive influx of calcium into the cytosol likewise leads to the opening of high-
conductance mtPTPs, aggravating the vicious circle in a process referred to as excitotoxicity. 
The role of PGC-1α in concerting antioxidant responses 
A number of evidence link PGC-1α to the regulation and activation of mitochondrial 
antioxidant responses. In a comprehensive study [4], the expression of PGC-1α significantly 
increased after H2O2 challenge in 10T1/2 cells, which effect was recapitulated by others on 
C2C12 muscle cells [13]. This is in correspondence with our recent findings of significantly 
increased PGC-1α mRNA expression in the CNS of mice intoxicated with the neurotoxin 3-
nitropropionic acid (3-NP), an irreversible inhibitor of complex II [14], and with a similar 
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finding by others on SH-SY5Y cells using 1-methyl-4-phenylpyridinium (MPP+), an 
irreversible inhibitor of complex I [15]. Furthermore, RNAi against PGC-1α reduced the 
baseline expression of Mn-SOD (SOD2), Cu/Zn-SOD (SOD1), and GPX in 10T1/2 cells, 
whereas the expression of Mn-SOD, Cu/Zn-SOD, and peroxisomal CAT was found reduced in 
the heart and brain of PGC-1α-deficient mice [4]. Similarly, overexpression of PGC-1α in C2C12 
myotubes lead to increased expression of Mn-SOD and GPX, in association with decreased 
ROS production [16]. Moreover, PGC-1α-deficient fibroblasts exhibited blunted response to 
ROS challenge and an increased sensitivity to oxidative stress. This is in correspondence with 
an increased sensitivity of PGC-1α-deficient mice to intoxication with 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), a prodrug of MPP+, as well as to that with the excitotoxin, 
kainate [4], and to the overexpression of α-synuclein [17]. 
I.3. The central role of mitochondrial dysfunction in degenerative CNS diseases – the 
contribution and therapeutic potential of PGC-1α 
A number of general observations and considerations explain the special susceptibility 
of the CNS to suffer injuries due to mitochondrial disturbances. Indeed, the CNS has an 
especially high energy demand as it represents merely 2% of the total body mass and accounts 
for some 20% of bodily oxygen consumption [18]. Besides, unlike astrocytes, neurons store 
low amounts of glycogen, and have a poor ability to enhance glycolysis under conditions when 
mitochondrial respiration is impaired [19]. Therefore, neurons depend on the constant 
availability of oxygen and glucose to maintain their functions. Furthermore, the CNS contains 
high amounts of polyunsaturated lipids, which are highly susceptible to oxidative injury by 
means of lipid peroxidation, and the antioxidant capacity of neurons is known to be relatively 
poor [20]. The high sensitivity of neurons as opposed to the relative resistance of astrocytes to 
oxygen or glucose deprivation is well known; however, recent studies suggest that 
oligodendrocytes are among the most sensitive cell types within the CNS to mitochondrial 
stress, exceeding the vulnerability of neurons [21, 22], a feature which may have implications 
for the pathogenesis of characteristic myelinopathies in chronic conditions with mitochondrial 
dysfunction, including aging and mitochondrial encephalopathies. The roles of mitochondrial 
dysfunction with particular focus on the involvement of PGC-1α in degenerative CNS disorders 
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is presented by a brief overview on the respective features of Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD), and mitochondrial encephalopathies. 
 
Alzheimer’s disease 
AD is a chronic, neurodegenerative disorder characterized by hippocampal, cortical, and 
basal forebrain cholinergic neurodegeneration and atrophy, associated with late-onset 
progressive dementia, which manifests in the loss of short-term and spatial memory and 
eventually most of the cortical functions. The process is accompanied by the formation of 
predominantly extracellular plaques of β-amyloid (Aβ) and intracellular deposits of 
neurofibrillary tangles constituted by hyperphosphorylated tau proteins (pTau). 
A line of evidence links the dysfunction of mitochondria to the pathogenesis of AD, 
which include a significant decrease in mitochondrial complex IV activity [23, 24], the 
excessive amount of mtDNA mutations [25], and the dysregulation of mitochondrial dynamics 
in AD neurons [26]. Additionally to the indirect elevation of ROS production through disrupted 
respiration, Aβ fragments per se generate free radicals [27], and there is a co-localization of the 
dense core plaques with the fluorescent signaling of free radicals, demonstrating a direct 
connection between Aβ and ROS generation [28]. Importantly, impaired protein processing in 
AD, i.e., the development of Aβ and Tau/pTau depositions, has been causatively linked to 
mitochondrial dysfunction, and in particular to oxidative stress [29] (Figure 2). 
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Figure 2. The involvement of mitochondrial dysfunction in Alzheimer’s disease. Complex 
IV deficiency, the predominant ETC disorder in sporadic PD has long been linked to the 
deleterious effects of β-amyloid accumulation, a pathognomonic alteration in AD. Disturbed 
OXPHOS leads to a vicious circle eventually resulting in cell death. Novel findings link PGC-
1𝛼 dysfunction to the pathogenesis of AD, the restoration of which may hold therapeutic value. 
(↑ = increased presence/expression/activity; ↓ = decreased presence/expression/activity; arrow 
= promotion; bulb-headed arrow = inhibition/deterioration.) Adapted from Szalárdy et al., 2012 
[29]. 
 
With regard to a potential role of PGC-1α in AD, Qin et al. reported an inverse 
correlation of hippocampal PGC-1α protein content with the severity of cognitive decline, 
neuritic plaque pathology and hippocampal Aβx-42 burden in AD patients. This group also 
provided in vitro evidence that PGC-1α deficiency might contribute to the accumulation of AD-
type Aβ in the brain via decreasing the non-amyloidogenic α-secretase activity [30]. On the 
other hand, impaired Presenilin-1 γ-secretase activity on amyloid precursor protein (APP) has 
recently been shown to downregulate PGC-1α expression in mouse embryonic fibroblasts and 
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in APP-deficient murine brains, contributing to decreased mitochondrial respiration and 
reduced levels of ATP in vitro [31]. Notably, exogenous upregulation of PGC-1α increased 
non-amyloidogenic APPα secretion and decreased amyloidogenic Aβ production via the 
deregulation of β-secretase in a PPARγ-dependent manner in vitro, a feature that may hold 
therapeutic relevance in AD, whereas downregulation of PGC-1α increased Aβ production [32]. 
Parkinson’s disease 
PD is a progressive, chronic neurodegenerative disorder, the pathognomonic alterations 
of which include loss of dopaminergic neurons and the presence of α-synuclein-rich deposits 
of Lewy bodies in the substantia nigra pars compacta (SNpc), with a subsequent decrease in 
striatal dopamine levels [33]. The leading clinical symptoms include bradykinesia, rigidity, 
resting tremor, and postural instability, evolving into severe akinesia, dementia, and eventually 
death. 
The development of sporadic PD is linked to a complex interplay of genetic and 
environmental factors, which have multiple implications for mitochondrial involvement (Figure 
3). The first implication for the role of mitochondrial dysfunction in PD came from serial cases 
of intoxication by the side-product of a synthetic illicit drug, MPTP, which evokes parkinsonian 
symptoms and recapitulates the majority of PD-related pathologies [34]. Its active metabolite 
MPP+ selectively and irreversibly impairs the function of mitochondrial complex I in 
dopaminergic neurons [35, 36]. Similar effects can be achieved by known environmental 
chemicals including the herbicide paraquat and the insecticide rotenone [37]. Corresponding 
with the ability of complex I inhibitors to evoke parkinsonism, a decreased activity and/or 
expression of respiratory complex I has been detected in the SNpc [38, 39], striatum [40] frontal 
cortex [41], platelets [42, 43], and skeletal muscle [44, 45] of sporadic PD patients, suggesting 
a systemic impairment of mitochondrial functions in this disease. In addition to the apparent 
involvement of mitochondrial dysfunction in sporadic PD, the majority of monogenic familial 
forms of PD are linked to a set of genes having direct implications in mitochondrial dysfunction 
(i.e., parkin, PINK1, DJ-1, LRRK2, and SNCA (encoding α-synuclein) [29]. 
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Alpha-synuclein, the main constituent of Lewy-bodies, may have central roles in PD, as 
its mitochondrial accumulation results in complex I inhibition [46, 47], a pathognomonic 
alteration in PD. The protein appears to play pivotal roles in modulating oxidative stress, as its 
transgenic overexpression leads to enhanced sensitivity against intoxication with paraquat and 
MPTP [48], whereas α-synuclein-deficiency leads to resistance against intoxication with MPTP 
and other mitochondrial toxins in mice [49]. Notably, there seems to be a bidirectional 
relationship between mitochondrial dysfunction and impaired protein handling in PD, as 
mitochondrial dysfunction itself can lead to the formation of α-synuclein inclusion bodies [50]. 
An increasing body of evidence suggests that PGC-1α may add important contributions 
to the pathogenesis of PD. Indeed, a comprehensive genome-wide meta-analysis found a set of 
425 PGC-1α-responsive nuclear-encoded mitochondrial genes underexpressed in sporadic PD, 
representing pinpoint defects in glucose metabolism and mitochondrial ETC [51]. Furthermore, 
associations of single nucleotide polymorphisms (SNPs) of PGC-1α has been reported with the 
risk of PD, the age of onset, and the longevity [52]. These appear to be in correspondence with 
the decreased expression of PGC-1α and its target gene NRF-1 in the SN and striatum of PD 
patients as well as in the midbrain of conditional parkin knockout mice [53]. In line with a 
decreased ATP production and impairments in mitochondrial OXPHOS [54] and antioxidant 
responses [4], mice deficient in PGC-1α have enhanced susceptibility to MPTP- [4] and α-
synuclein-induced toxicity [17], with alterations in mitochondrial dynamics preferentially 
affecting nigral dopaminergic neurons [17]. Corresponding to the observations that 
mitochondrial dysfunction can promote the aggregation of α-synuclein [50], the reduced 
expression of PGC-1α in vitro lead to enhanced α-synuclein oligomerization [55]. 
Calling for a potential therapeutic relevance in PD, the overexpression of PGC-1α 
demonstrated neuroprotection against α-synuclein-induced toxicity in vitro [51, 56] and in 
PGC-1α-deficient mice in vivo [17], against MPP+ [15] and rotenone toxicity in vitro [51], and 
in a parkin interacting substrate (PARIS) overexpression model of PD in vivo [53]. In line with 
these, transgenic overexpression and resveratrol-induced activation of PGC-1α (via 
deacetylation by Sirt-1) both rendered neuroprotection against MPTP toxicity in mice [57]. 
Similarly, the PPARγ agonist pioglitazone, capable of enhancing the activity and expression of 
PGC-1α [58], was also protective in MPTP studies [59, 60]. However, contrasting preclinical 
results have also been published [61, 62], and, disappointingly, a phase II safety and futility 
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clinical trial with pioglitazone on patients with early PD has recently demonstrated no clear 
benefit compared to placebo with the doses applied (NCT01280123) [63]. 
 
 
 
 
Figure 3. The involvement of mitochondrial dysfunction in Parkinson’s disease. Complex 
I deficiency, the predominant ETC disorder in sporadic PD is linked to the deleterious effects 
of 𝛼-synuclein aggregation, a pathognomonic alteration in PD, and inhibitors of complex I 
(such as MPTP, rotenone, and paraquat) are used in experimental modeling of PD. Most of the 
genes associated with familial PD have direct implications in mitochondrial dysfunction. 
Disturbed OXPHOS leads to a vicious circle eventually resulting in cell death. Novel findings 
link PGC-1𝛼 dysfunction to the pathogenesis of sporadic PD, the restoration of which may hold 
therapeutic value. (↑ = increased presence/expression/activity; ↓ = decreased 
presence/expression/activity; arrow = promotion; bulb-headed arrow = 
inhibition/deterioration.) Adapted from Szalárdy et al., 2012 [29]. 
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Huntington’s disease 
Huntington’s disease (HD) is a monogenic, progressive neurodegenerative disease of 
autosomal dominant inheritance. The genetic alteration is the expansion of CAG trinucleotide 
repeat sequence on the interesting transcript 15 (IT15) gene on chromosome 4 encoding 
huntingtin, with increasing number of repeat associating with earlier onset and more rapid 
progression [64]. The disease onset is usually between 40-50 years of age, presenting with 
behavioral alterations and hyperkinetic movement disorders (i.e., chorea, ballism) in the early 
stages, subsequently associating with pyramidal symptoms, dystonia, dementia, and psychosis. 
The pathognomonic alteration is the preferential loss of the striatal γ-aminobutyric acid 
(GABA)-ergic medium-sized spiny projection neurons (MSNs), and the presence of 
intracytoplasmic and intranuclear protein inclusions of mutant huntingtin, widely distributed in 
neuronal as well as extraneuronal tissues. 
The characteristic decreased activity of respiratory complex II, especially in the 
striatum, has early linked HD to mitochondrial dysfunction [65], an alteration that appears to 
be crucial in HD, as its overexpression demonstrated marked restorative effect in animal models 
[66-68]. In line with these, irreversible or reversible inhibition of complex II by 3-NP [69, 70] 
and malonate [71], respectively, effectively recapitulates most of the clinical and 
histopathological characteristics of HD. Supportive data for a primary role of mitochondrial 
dysfunction in mediating the effects of mutant huntingtin include an increased presence of 
oxidative stress [72, 73], an increased amount of mtDNA mutations [74], disturbances in 
mitochondrial trafficking [75], a gradually decreasing mitochondrial number [76], and an 
impairment of mitochondrial calcium handling [77] observed in HD patients, with an enhanced 
sensitivity to calcium-induced opening of mtPTP and cytochrome c-mediated cell death [78, 
79] (Figure 4). 
A PGC-1α-dependent thermoregulatory defect in transgenic HD mice was the first to 
suggest the contribution of PGC-1α- dysfunction in the pathogenesis of HD [80]. Indeed the 
expression of PGC-1α has been found downregulated in the striatum of HD patients [76, 80-
82], in transgenic HD animals [14, 80, 81, 83-85], and in in vitro HD models [81, 82, 85, 86]. 
Correspondingly, the decreased expression of several PGC-1α target genes have been identified 
in the striatum of HD patients [76, 80] and transgenic HD mice [80, 83, 84]. A possible 
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mechanism through which mutant huntingtin can lead to the downregulation of PGC-1α can be 
secondary to its effect to enhance the expression [87] and activity of NR2B subunit-containing 
NMDA receptors [88], features characteristic of transgenic HD mice [89], which in turn results 
in a decreased striatal CREB signaling [89], and a subsequent downregulation of PGC-1α [90]. 
 
 
 
Figure 4. The involvement of mitochondrial dysfunction in Huntington’s disease. Complex 
II deficiency, the predominant ETC disorder in HD has long been linked to the deleterious 
effects of mutant huntingtin aggregation, a pathognomonic alteration in HD, and inhibitors of 
complex II (such as 3-NP and malonate) are used in experimental modeling of the disease. 
Disturbed OXPHOS leads to the development of a vicious circle, eventually resulting in cell 
death. Novel findings link PGC-1𝛼 dysfunction to the pathogenesis of HD at multiple levels, 
the restoration of which may hold therapeutic value. (↑ = increased 
presence/expression/activity; ↓ = decreased presence/expression/activity; arrow = promotion; 
bulb-headed arrow = inhibition/deterioration.) Adapted from Szalárdy et al., 2012 [29]. 
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A possible mechanism through which mutant huntingtin can lead to the downregulation 
of PGC-1α can be secondary to its effect to enhance the expression [87] and activity of NR2B 
subunit-containing NMDA receptors [88], features characteristic of transgenic HD mice [89], 
which in turn results in a decreased striatal CREB signaling [89] and a subsequent 
downregulation of PGC-1α [90]. In addition, a decreased expression of transducer of regulated 
CREB-binding protein 1 (TORC1), an activator of CREB-mediated PGC-1α expression, has 
been found in post mortem HD striatum, in transgenic HD mice and in an in vitro HD model, 
which may contribute to the downregulation of PGC-1α expression in HD [86], whereas others 
suggest that PGC-1α repression may be secondary to the downregulation of PPARγ in HD [85]. 
Corresponding with the concept of an important contribution, polymorphisms in the 
PPARGC1a gene encoding PGC-1α have been found to modify the age at onset of HD [91, 92]. 
Supporting a potential therapeutic relevance, a line of evidence suggests that 
mechanisms associated with the upregulation of PGC-1α can exert neuroprotection in 
experimental models of HD. Indeed, PPARγ agonists thiazolidinediones (such as rosiglitazone 
and pioglitazone) were proven to be protective in transgenic [84, 85, 93], quinolinic acid-
induced [94] and 3-NP-induced rodent [95], and in in vitro models of HD [85, 93, 96]. 
Similarly, the pan-PPAR agonist, bezafibrate, exerted protection in transgenic HD mice [97]. 
Furthermore, TORC1 activation displayed protective and restorative effects on viability and 
mitochondrial functions in a striatal HD cell line model exposed to 3-NP [86]. Likewise, 
transgenic overexpression or Sirt-1 overexpression-induced upregulation of PGC-1α restored 
the diminished mitochondrial number in 120Q huntingtin-overexpressing cortical neurons [56]. 
The protective effect of resveratrol, a polyphenol with potent Sirt-1/PGC-1α-activating 
properties, has also been demonstrated in transgenic murine and nematode models [98], in a 3-
NP-induced murine model [99], and in an in vitro model of HD [98]. A phase III clinical trial 
with resveratrol in HD is currently recruiting its participants (NCT02336633). 
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Mitochondrial spongiform encephalopathies 
Mitochondrial diseases are a group of multisystemic disorders where the characteristic 
pathologies affecting organs with high energy demand (i.e., brain, liver, heart, skeletal muscle, 
and kidney) are due to mitochondrial dysfunction as a consequence of a sporadic or inherited 
genetic alteration either in the mtDNA or in the nDNA. The deleterious loss of functions may 
affect several components of proper mitochondrial functioning, including genes encoding 
respiratory complex subunits, proteins responsible for mtDNA transcription/translation, 
mitochondrial tRNAs and rRNAs, as well as nuclear-encoded ancillary proteins of 
mitochondrial function [100]. The diseases are distributed to characteristic syndromes based on 
the clinical manifestation and the observed neuropathological alterations, including Leigh 
syndrome (LS), Kearns-Sayre syndrome (KSS), mitochondrial encephalomyopathy, lactic 
acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fibers 
(MERRF), neuropathy, ataxia, retinitis pigmentosa (NARP), and mitochondrial 
neurogastrointestinal encephalopathy (MNGIE) [101-104]. In these diseases, impaired ATP 
production with various defects in respiratory complexes and excess ROS production in the 
affected tissues have widely been documented and have been excessively reviewed [105]. 
Though in somewhat different patterns, mitochondrial encephalopathies are collectively 
characterized by various degrees of tissue vacuolation in the white (WM) and grey matter (GM) 
of the CNS, accompanied by region-selective reactive astrocytosis with-or without 
neurodegeneration (the latter case is also referred to as ‘pseudonecrosis’). 
Though no mutations of PGC-1α have been directly associated with a phenotype of 
mitochondrial disease, considering the spectrum of roles of PGC-1α in regulating and 
promoting mitochondrial functions and the fact that a number of genes involved in disease-
causing mutations and/or that involved in modeling mitochondrial disease have direct or 
indirect interactions with PGC-1α (e.g., adenine nucleotide translocator-1 (ANT-1), mtDNA 
polymerase γ 1 (POLG1), Tfam, NRF-1, NRF-2, PPARs, ERRs, Mn-SOD, and CREB), the 
rationale for PGC-1α induction to provide symptomatic benefit in these currently intractable 
groups of diseases can be accepted [106]. Indeed, transgenic or bezafibrate-induced 
overexpression of PGC-1α delayed the onset of symptoms in a cytochrome c oxidase-deficient 
murine model of mitochondrial mypopathy [107]. Similarly, transgenic overexpression of 
PGC-1α ameliorated the phenotype and increased the activity of mitochondrial respiratory 
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complexes in POLG1 mutant ‘Mutator’ mice [108]. Furthermore, adenoviral overexpression of 
PGC-1α partially restored respiratory deficits in fibroblasts obtained from patients with 
mitochondrial disease of various origin (though to different efficacy) and in MELAS cybrids 
[109]. These together suggest a potential therapeutic relevance of boosting mitochondrial 
biogenesis via PGC-1α-mediated approaches in diseases with a genetic mitochondrial disorder. 
I.4. PGC-1α-deficient animals – intriguing contradictions 
PGC-1α has recently been described to undergo an alternative 3’ splicing between exons 
6 and 7, which produces an in-frame stop codon at amino acid 268, resulting in a shorter but 
functionally active splice variant of PGC-1α called N-truncated or N-terminal fragment of 
PGC-1α (NT-PGC-1α; comprising 267 amino acids) [110] (Figure 5). In the past years, two 
independently developed whole-body knockout murine strains of PGC-1α have been generated. 
Despite its well-established contributions in mitochondrial functions, the absence of PGC-1α is 
compatible with life. Correspondingly, the developed knockout mice are viable and fertile [111, 
112], suggesting the presence of functional compensatory pathways. Importantly, the first 
whole-body knockout strain generated by Lin et al. represents a complete knockout of PGC-1α 
[111], displaying no residual expression of any fragments of the protein (PGC-1α -/-). 
Meanwhile, the parallel-developed whole-body knockout strain described by Leone et al. [112], 
however, lacks the expression of the full-length protein (FL-PGC-1α -/-) but readily expresses 
a slightly shorter form of the splice variant NT-PGC-1α, denoted as NT-PGC-1α254, which has 
recently been shown to be functionally identical with the complete NT splice variant [113] 
(Figure 5). Notably, both PGC-1α whole-body knockout strains were reported to display 
astrogliosis and tissue vacuolation in the brain, predominantly in the striatum, which led to the 
conclusion that PGC-1α deficiency may model neurodegeneration, more particularly HD. 
These appeared to be in correspondence with early findings of reduced striatal expression of 
PGC-1α and its target genes in the striatum of HD patients [80, 81] as well as in its transgenic 
in vivo [14, 80, 81] and in vitro models [80, 81], as discussed above. It must be noted, however, 
that no reports have yet provided direct evidence of striatal neuronal loss in PGC-1α-deficient 
mice. Notably, a number of interesting differences were observed between the two strains, 
including an intact hepatic gluconeogenesis and the adult onset obesity seen in FL-PGC-1α -/- 
mice. More intriguingly, in the first pioneering publication, the complete PGC-1α -/- mice were 
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reported to exert hyperactivity, a behavioral feature which was interpreted as HD-like 
hyperkinetic phenotype [111]. Contrastingly, the second pioneering publication on FL-PGC-1α 
-/- mice reported hypomotility and weakness [112]. 
 
Figure 5. Full-length (FL) and N-truncated (NT) isoforms of PGC-1α protein, and the 
residual fragment expressed in FL-PGC-1α -/- mice. While a number of coactivator domains 
are functional in the NT isoform, coactivator domains of target proteins essential in 
mitochondrial biogenesis and respiration are apparently lacking. Adapted and modified from 
Knutti and Kralli, 2001 [114]. 
 
II. OBJECTIVES 
In light of the above-reviewed literature about the contribution of mitochondrial and in 
particular PGC-1α-related dysfunction in the different aspects of the pathogenesis of 
degenerative CNS diseases, our objectives were to further explore and characterize the effects 
of PGC-1α deficiency in vivo along two pillars. 
1) Based on the concordant data linking mitochondrial dysfunction and PGC-1α deficiency 
to the dysregulation of neuronal protein processing and handling in neurodegenerative diseases 
(i.e., demonstrated enhancement of accumulation of α-synuclein [55] and β-amyloid [30] due 
to PGC-1α deficiency in in vitro models of PD and AD, respectively), we performed a 
systematic neuropathological characterization of adult mice lacking the expression of FL-PGC-
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1α, with special focus on the immunohistochemical pattern of neurodegeneration-related 
proteins. 
 
2) PGC-1α-deficient animals were reported to exhibit vacuolation and reactive gliosis in 
the striatum [111, 112] accompanied by hyperkinetic behavior [111], which were interpreted as 
features typical of HD. As neither brain vacuolation (which was, however, not isolated to the 
striatum [111]) nor hyperkinetic behavior is typical feature of transgenic or systemic toxin-
induced model mice of HD, our aim was to create a comprehensive neuropathological lesion 
profile of FL-PGC-1α -/- animals, characterizing neuronal, axonal, astroglial, oligodendroglial, 
and myelinic pathologies. As the initial results linked the neuropathological phenotype to 
mitochondrial disease, the animals were systematically compared with human brain tissue 
samples from a case with definite mitochondrial encephalopathy. 
 
III. MATERIALS AND METHODS 
III.1. Animals 
FL-PGC-1α -/- mice developed on C57Bl/6J background were generated in Kelly Lab 
(Sanford-Burnham Institute for Medical Research at Lake Nona, Orlando, FL, USA) [112] and 
bred further in the Department of Neurology, University of Szeged. The animals were housed 
in cages (maximum 4 per cages) in standard conditions with 12-12 h light-dark cycle and ad 
libitum access to standard pellet food and water. The experiments were performed in accordance 
with the European Communities Council Directive (86/609/EEC) and were approved by the 
local animal care committee. 
III.2. Histopathology, immunohistochemistry, and electron microscopy 
For the first set of neuropathological work-up, 15 FL-PGC-1α -/- (8 male, 7 female) and 
16 (8 male, 8 female) age-matched 30-week-old wild-type C57Bl/6J mice were involved. 
Brains were removed on ice and halved at the midline immediately following decapitation. Half 
brains were fixed in 4% paraformaldehyde overnight and kept in 10% glycerol in 4°C until 
embedding in paraffin. The other half of the brains were used for frozen sections (i.e., for Oil 
Red O staining). 4-μm-thick sagittal sections of paraffin-embedded murine brain halves were 
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evaluated. We performed the stainings at two levels, one in the level containing the septal 
nuclei, the medial thalamus, and the retroflex fascicle, and one in the level of the caudate-
putamen, containing also the substantia nigra. In addition to Hematoxylin and Eosin (H&E), 
Klüver-Barrera (Luxol and Fast red), and Bielschowsky silver stainings, the following 
monoclonal antibodies (cross-reacting with mouse) were used for immunohistochemistry: anti-
pTau AT8 (pS202/pT205, 1:200, Pierce Biotechnology, Rockford, IL, USA), anti-α-synuclein 
(1:10.000, clone 4D6, Signet, Dedham, MA, USA), anti-Aβ (1:50, clone 6F/3D, Dako, 
Glostrup, Denmark), anti-APP (1:500, Millipore, Billerica, MA, USA), and anti-prion protein 
(PrP; 6H4, 1:1000, Prionics, Schlieren, Switzerland; epitope 144-152). Furthermore, the 
following polyclonal antibodies were used: anti-ubiquitin (1:1000, Dako), anti-glial fibrillary 
acidic protein (GFAP, 1:3000, Dako) anti-TDP-43 (1:100, ProteinTech Group, Chicago, IL, 
USA), anti-tau (1:100, Dako; cross-reacts with the tau-equivalent protein in mouse), and anti-
FUS (1:1000, Sigma-Aldrich, St. Louis, MO, USA) antibodies. The DAKO EnVision detection 
kit, peroxidase/DAB, rabbit/mouse (Dako) was used for visualization of antibody reactions. 
When applying mouse antibodies, we used the M.O.M. kit (Vector Laboratories, Burlingame, 
CA, USA) to prevent the aspecific background staining of endogenous mouse 
immunoglobulins. As positive controls for the immunostaining, we used tissue sections from 
human AD (pTau and Aβ), PD (α-synuclein) and frontotemporal lobar degeneration (FTLD) 
with TDP-43 or FUS inclusions (TDP-43 and FUS) as well as tissue sections from scrapie-
infected mice (PrP, RML strain, Hamilton, MT, USA). 
During neuropathological profiling, alterations (vacuolation and astrogliosis) were 
semiquantitatively evaluated in several anatomical regions (Table 1). Respecting the fact that 
vacuole-like alterations may also develop due to histological preparatory processes, vacuoles 
were scored 0–4 as follows (Figure 6A): 0) No vacuoles or scattered vacuole-like alterations 
but not more than 1 per visual field at 40x magnification; 1) Scattered vacuole-like alterations 
but not more than 3 per visual field at 40x magnification; 2) Mildly vacuolated lesion(s) with 
less than 10 vacuoles per visual field at 40x magnification; 3) Moderately vacuolated lesion(s) 
with less than 20 vacuoles per visual field at 40x magnification; 4) Severely vacuolated lesion(s) 
with more than 20 vacuoles per visual field at 40x magnification. Astrogliosis were scored 0-3 
as follows (Figure 6B): 0) No astrocytes or scattered resting asctrocytes; 1) Cloudy positivity 
with no signs of reactivation; 2) Moderate astrogliosis with multiple reactive astrocytes in a 
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patchy distribution; 3) Severe astrogliosis with abundant reactive astrocytes in a confluent 
pattern. 
 
 
 
Figure 6. Representative images corresponding to the semiquantitative scores used to evaluate 
vacuolation (A) and astrogliosis (B) in FL-PGC-1α -/-. Bar in a represents 20 μm. Original 
publication in: [115]. 
 
 
For the second set of neuropathological work-up, 8-8 remarkably older 70-75-week-old 
FL-PGC-1α -/- and age-matched wild-type C57Bl/6J male mice were sacrificed and evaluated 
with half brains prepared and fixed as above. A total of 6 (four 30-35-week-old, one 70-week-
old and one 100-week-old) FL-PGC-1α -/- animals and 3 wild-type (one from each age group) 
used for electron microscopy; animals were anesthetized with isoflurane and were perfused 
transcardially with modified Hamori fixative (1.5% glutaraldehyde and 1% formaldehyde in 
phosphate buffer) for 18 min with a 10 ml/min flow, prior to decapitation, subsequent 
postfixation, and sample preparation. 
Based on the results of the first set of neuropathological examinations [115], the 
alterations were systematically compared with corresponding samples from human brain tissue 
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of a male patient with a mitochondrial disease died at 22 years of age, who carried a 4.9 kbp 
common deletion in mtDNA with a heteroplasmy ratio of 50%, characteristic of KSS. The 
mother gave informed consent prior to the neuropathological work-up, and the study was 
adhered to the tenets of the most recent revision of the Declaration of Helsinki. 
Formalin-fixed paraffin-embedded blocks of different regions of the KSS brain, 
including several neocortical areas, basal ganglia, thalamus, hippocampus, amygdala, 
brainstem, and cerebellum, as well as a double hemispheric block at the levels of WM lesions 
were examined. For electron microscopy, human KSS samples from the basal ganglia (internal 
capsule) and WM lesions were immersion-fixed in 4% glutaraldehyde for 3 days. Human and 
murine brain sections for conventional histology were stained with Klüver-Barrera and Oil Red 
O stainings. The murine brains were subjected to staining with anti-pTau AT8, anti-α-
synuclein, anti-Aβ monoclonal, and anti-ubiquitin, anti-tau, anti-TDP-43, and anti-FUS 
polyclonal antibodies for immunohistochemical assessment of neurodegeneration-related 
proteins, as described above. In addition, monoclonal antibodies (cross-reacting with mouse) 
against APP, phosphorylated and non-phosphorylated neurofilaments (clones SMI-31 and SMI-
32, markers of axons and neuronal cell bodies; 1:5000 and 1:200, respectively, Covance, 
Berkeley, CA, USA), TPPP/p25 (1:2000; a marker of mature oligodendrocytes [116]) and 
microtubule-associated protein-2 (MAP-2, marker of neuronal cell bodies and dendrites; 1:500, 
Millipore), as well as polyclonal antibodies against GFAP, myelin basic protein (MBP; 1:400, 
Dako) and anti-Iba1 (1:1000, Wako Chemicals, Osaka, Japan) were used. The DAKO EnVision 
detection kit was also used for visualization of antibody reactions. We used the M.O.M. kit as 
above where appropriate. 
For electron microscopic evaluation, the obtained samples from both human and murine 
brains were postfixed in 1% osmium tetroxide for 1-2 h, dehydrated through a series of graded 
ethanols and propylene oxide, and then embedded in Embed 812 resin (Electron Microscopy 
Sciences, EMS 14120). Semi-thin sections were stained with toluidine blue, blocks trimmed, 
and ultrathin sections stained with lead citrate and uranyl acetate. Specimens were examined 
using a JEM-100C transmission electron microscope. 
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III.3. Statistical analysis 
The statistical evaluation of the data was carried out by SPSS Statistics 17.0 software®. For 
evaluation of scored neuropathological alterations, cross-tabulation analyses of the discrete 
variables were performed using the Fisher’s exact test. In structures large enough to be present 
in both the paramedian and the lateral sections, we performed a statistical analysis for the 
estimation of difference within the FL-PGC-1α -/- animals. A p value < 0.05 was regarded as 
significant. Structures with statistically significant medio-lateral difference were dealt 
separately; otherwise, pooled data were used for the comparative analysis of FL-PGC-1α -/- 
and wild-type brain structures. 
 
IV. RESULTS 
IV.1. Immunostaining for neurodegeneration-related proteins 
Immunostaining for PrP revealed moderate staining of the neuropil, and for α-synuclein 
we observed immunopositivity in presynaptic structures. Anti-APP and anti-phospho-
independent tau antibodies showed cytoplasmic immunoreactivity, while for TDP-43, FUS, and 
ubiquitin, nuclear staining pattern was observed. All of these were the same in wild-type and 
FL-PGC-1α -/- animals in any age group examined. Moreover, there was a complete lack of 
tangle-like structures, pretangles, glial or astrocytic tau pathology, extracellular plaques (Aβ or 
PrP) and TDP-43, FUS, or ubiquitin-immunopositive inclusion bodies (nuclear or cytoplasmic) 
in all animals and brain regions (Figure 7). This picture was virtually identical when examining 
70-75-week-old FL-PGC-1α -/- mice in a subsequent experimental setting (data not shown). 
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Figure 7. The absence of FL-PGC-1α expression is not associated with the accumulation 
of neurodegeneration-related proteins in 30-week old adult mice. Immunostaining for prion 
protein (PrP), α-synuclein (a-Syn), amyloid precursor protein (APP), amyloid-beta (A-beta), 
Tau, pTau, TDP-43, FUS, and ubiquitin (Ubi) in various anatomical regions in wild-type (WT) 
and FL-PGC-1α -/- (PGC-1α) animals. The representative images demonstrate the lack of 
pathological protein aggregation and inclusion body formation with physiological staining 
patterns throughout the brain of mature FL-PGC-1α -/- mice. Original publication in: [115]. 
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IV.2. Lesion profile analysis of adult FL-PGC-1α -/- mice 
At 30 weeks of age, neuropathological changes included vacuolation, predominantly in 
the WM, and reactive astrogliosis in certain brain regions. 
Spongiform alterations were present throughout the brain in FL-PGC-1α -/- mice. The 
caudate-putamen was the most severely affected GM structure (Figure 8A), followed by the 
antero-lateral nuclei of the thalamus (reticular and ventral posterolateral area), but consistent 
mild-to-moderate alterations could be observed in the pontomedullary brainstem, tegmental 
midbrain, nucleus accumbens, globus pallidus, medial thalamus, mammillary body, substantia 
nigra, the cerebellar nuclei, as well as throughout the neocortex (Table 1). However, 
vacuolation was lacking in the cerebellar cortex, tectal midbrain, and septal nuclei. Vacuoles 
within the neocortex predominated in the deep cortical layers; furthermore, the analysis of 
cerebral cortices in the lateral sections revealed a preference towards the posterior (visual and 
sensory) versus the anterior (motor, insular, and piriform) cortices (Fisher’s exact value = 
19.184; p < 0.001). Spongiform change in the pontomedullary brainstem was more severe in 
the paramedian than in the lateral sections (Fisher’s exact value = 9.282; p = 0.018). 
In WM structures, robust vacuolation was observed in the internal capsule (Figure 8A) 
and the retroflex fascicle, mild-to-moderate alterations were noted in the cerebellar WM, the 
fimbria hippocampi, the stria terminalis, the anterior commissure, and the olfactory tract, 
whereas the optic tract remained consistently unaffected. Vacuolation of the myelin, which was 
arranged in chains in the severely affected WM regions, was not associated with apparent 
axonal injury, as indicated by the lack of argyrophilic axonal swellings (Figure 8B), excluding 
robust morphological evidence of a disturbance in axonal transport. Notably, in the 
hippocampus, consistent vacuolation was mainly observed in the WM bundles of the lacunosum 
molecular layer of the cornu Ammonis (CA)1 (Figure 8C), whereas its GM structures, the CA1-
3 and the dentate gyrus, were relatively preserved. Similarly, the Klüver-Barrera staining of the 
caudate-putamen revealed that the vacuoles within the caudate-putamen were the most 
abundant in the streaming fibers of the anterior internal capsule (pencil fibers) (Figure 8C). All 
these raised the possibility that at least a proportion of vacuoles previously considered to be 
localized within the neuropil might be situated also within WM structures. 
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Figure 8. Vacuolation in the brains of adult FL-PGC-1α -/- mice is reminiscent of human 
mitochondrial leukoencephalopathies. (A) H&E staining in different anatomical regions in 
wild-type (WT) and FL-PGC-1α -/- (PGC-1α) animals demonstrates prominent vacuolation in 
the caudate-putamen and the internal capsule in FL-PGC-1α -/- animals. (B) Vacuolation in the 
WM (as shown by Klüver-Barrera staining on the middle left) often exhibits chain-like 
appearance and is associated with seemingly well-preserved axons, pushed towards the edge of 
the vacuoles (as shown by Bielschowsky silver staining on the middle right). (C) Vacuoles in 
the neuropil appear to associate with WM structures as revealed by Klüver-Barrera staining of 
the hippocampus (lacunosum molecular layer) and the caudate-putamen (pencil fibers). 
Original publication in: [115]. 
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Indicative of chronic neuronal degeneration, prominent reactive gliosis was present in 
the brainstem and within the cerebellar nuclei of FL-PGC-1α -/- mice. This was the most 
striking in the paramedian sections of the pontomedullary brainstem, whereas moderate 
astrogliosis was noted in the midbrain, the cerebellar nuclei, and the lateral pontomedullary 
brainstem (Figure 9). The median predominance of the involvement of the pontomedullary 
brainstem was statistically significant (Fisher’s exact value = 10.758; p = 0.004). No other 
regions of the brain displayed any signs of astrocytic reactivation. Moreover, we did not observe 
pathological degree of vascular proliferation in any examined region (data not shown). 
 
 
Figure 9. Immunostaining for GFAP showed reactive astrogliosis indicative of chronic 
neuronal degeneration in the pontomedullary brainstem and certain deep cerebellar nuclei but 
not in the caudate-putamen of adult FL-PGC-1α -/- animals. Original publication in: [115]. 
 
Concluding these initial results, the observed lesion profile did not recapitulate features 
characteristic of neurodegenerative diseases (including HD, AD, and PD) either in terms of 
impaired protein processing or the localization of signs of neuronal degeneration. However, 
with wide-spread vacuolation predominantly affecting the WM of the basal ganglia, thalamus, 
brainstem, and cerebellum, as well as reactive astrogliosis in the brainstem and deep cerebellar 
nuclei, the observed picture was remarkably reminiscent of that seen in mitochondrial 
spongiform leukoencephalopathies, in particular the KSS (Table 2) [115]. 
This prompted us to further explore and characterize the observed lesion profile in a 
systematic comparison of aged FL-PGC-1α -/- animals and a human brain with KSS by the use 
of further immunohistochemical and electron microscopic techniques, with a special focus on 
the origin of vacuoles [117]. 
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Typical degree of vacuolation Region Mean p-value 
Mild 
cerebellar WM  1.833 < 0.001 
pontomedullary brainstem l * 1.923    0.005 
substantia nigra 1.375    0.004 
hippocampus m 1.133    0.006 
hippocampus l 1.933 < 0.001 
fimbria hippocampi 1.182    0.007 
Moderate 
cerebellar nuclei * 2.150 < 0.001 
pontomedullary brainstem m ** 2.933 < 0.001 
midbrain * 2.571 < 0.001 
nucleus accumbens 2.600 < 0.001 
globus pallidus 2.692 < 0.001 
mammillary body 2.143 < 0.001 
cerebral cortex 2.305 < 0.001 
thalamus 
m 2.067 < 0.001 
anterior commissure 2.533 < 0.001 
stria terminalis 2.786 < 0.001 
olfactory tract 2.071 < 0.001 
Severe  
caudate-putamen 4.000 < 0.001 
thalamus 
l 3.533 < 0.001 
internal capsule 3.615 < 0.001 
retroflex fascicle 4.000 < 0.001 
l lateral section; m paramedian section; * accompanied by moderate astrogliotic reaction; ** 
accompanied by severe astrogliotic reaction. 
Table 1. Lesion profile in the brains of FL-PGC-1α -/- mice. Comprehensive mapping of 
lesion profile in FL-PGC-1α -/- animals, demonstrating the typical degree of involvement of an 
anatomical region in the spongiform vacuolation and reactive astrogliosis. The differences 
between FL-PGC-1α -/- and wild-type animals are represented by the means and the 
corresponding p values in the respective anatomical regions. Original publication in: [115]. 
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IV.3. Comparison of lesion profiles between human KSS and aged FL-PGC-1α -/- mice 
Vacuolation 
 Klüver-Barrera staining revealed widespread spongiform change in both the KSS brain 
and 70-75-week old aged FL-PGC-1α -/- mice. In both, the vacuolation predominated in the 
WM; however, vacuoles in the GM neuropil were also observed with apparently lower 
frequency (Figure 10A-F). The vacuolation commonly affected the internal capsule, striatal 
pencil fibers, cerebellar WM, thalamic fascicules, pyramidal tracts, and, less intensively, the 
corpus callosum. Vacuoles were commonly present in the neuropil, most intensively in the 
brainstem, but also consistently present in the basal ganglia, thalamic nuclei, and, less 
intensively, in the neocortex, where they showed a predilection towards the deep cortical layers. 
The severity of vacuolation was more prominent in the KSS brain than in experimental animals; 
in some regions with coarse cystic-necrotic lesions and myelin pallor, whereas in some others 
with demyelinated foci (e.g., postcentral region, cerebellar WM, and some of the pencil fibers) 
(Figure 10C and F). Demyelination and cystic-necrotic lesions were undetected in FL-PGC-1α 
-/- mice. Notably, the examined aged wild-type brains presented vacuoles showing similar 
appearance and distribution as their FL-PGC-1α-deficient counterparts; however, their 
frequency was remarkably lower in all examined regions (Figure 10A-B and D-E). 
Astrogliosis 
 GFAP staining revealed moderate-to-severe reactive astrogliosis in the brainstem and 
cerebellum of both the KSS and the FL-PGC-1α-deficient brains (Figure 10G-I). In the KSS 
brain, astroglial reaction was observed in the tectal midbrain, the area of the inferior olive in 
the medulla oblongata, the dentate nucleus of the cerebellum, and the Purkinje cell layer (i.e., 
Bergmann gliosis). In the FL-PGC-1α-deficient mice, severe reaction was present in the 
medulla oblongata and the pons often in a confluent pattern involving large areas without being 
limited to certain groups of nuclei, whereas mild reaction with patchy astrocytosis was observed 
in the midbrain and in the deep cerebellar nuclei. Notably, the caudate-putamen of FL-PGC-1α 
-/- mice were free of astroglial reaction even at this age (Figure 11), supporting our prior 
observations [115]. 
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Figure 10. Vacuolation and astroglial reaction. Aged FL-PGC-1α-deficient mice develop 
moderate-to-severe vacuolation (B and E) in areas corresponding to severe-to-devastating 
vacuolation in KSS (C and F) and mild vacuolation in aged wild-type mice (A and D; Klüver-
Barrera). Vacuoles are in association with WM structures. Note the patchy areas of myelin 
pallor in the pencil fibers of the caudate-putamen (C) and the demyelinated cystic-necrotic 
lesion in the cerebellar WM in KSS (F). Reactive astrogliosis indicative of neuronal 
degeneration is present in the brainstem of FL-PGC-1α-deficient mice and the KSS case (H and 
I; GFAP). Original publication in: [117]. 
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Figure 11. The caudate-putamen of FL-PGC-1α -/- mice is free of reactive astrogliosis (GFAP) 
even at 70-75 weeks of age, suggesting that this murine strain is not a model for HD, as it was 
previously suggested. Original publication in: [117]. 
Axonal pathology 
 The intensity of axonal destruction in the KSS brain was variable and generally followed 
that of the vacuolar change. Only the severely affected cystic-necrotic lesions showed axonal 
loss or swelling, whereas most of the moderately vacuolated areas were devoid of axonal 
pathology (Figure 12C), except for scattered swellings and APP-positive spheroids indicating 
acute-subacute impairment of axonal transport (Figure 12F). Regions with severe axonal 
involvement were accompanied by reactive microgliosis (Figure 12I). The axons in FL-PGC-
1α -/- mice were generally well preserved with patterns of APP, neurofilament and microglia 
stainings being similar to that seen in wild-type (Figure 12A-B, D-E, and G-H). 
Characterization of white matter vacuoles 
 Vacuoles within the WM were surrounded by rings of MBP-positive myelin in both the 
KSS and FL-PGC-1α-deficient brains (Figure 13A). The vacuoles were usually ovoid with their 
longitudinal axis paralleling the direction of axons. They often formed chain-like structures in 
longitudinal or sieve-like lesions in transverse sections. No apparent macrophage activity was 
present even in the areas of severe vacuolation, and no signs of active myelin degradation could 
be detected by Oil Red O (not shown). 
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Figure 12. Axonal pathology. Axons in moderately vacuolated areas in KSS are relatively 
intact with scattered appearance of axonal swellings (C; SMI-31) and APP+ axonal spheroids 
indicative of subacute axonal transport impairment (F; APP). Regions with cystic-necrotic 
lesions show robust microglia accumulation in KSS (I; Iba). These pathologies are virtually 
absent in the FL-PGC-1α -/- mice and the immunohistochemical patterns are rather similar to 
that in aged wild-types (A-B, D-E, and G-H). Note the well-preserved axons dodging between 
multiple vacuoles (B), similarly to that seen in KSS (C). Original publication in: [117]. 
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Electron microscopy revealed that myelin ‘bubbles’ in the WM were formed mostly by splitting 
at the intraperiod lines (Figure 14A-B), and in the KSS material (where countless vacuoles 
could be analyzed) occurrences between the axons and the innermost myelin lamellae (adaxonal 
vacuoles) could also be noticed (Figure 15). The vacuoles were ‘empty’ or contained various 
amount of debris with myelin-like figures (Figure 14A-B, Figure 15). 
Characterization of neuropil vacuoles 
Staining for neuronal (MAP-2 and SMI-32) or astrocytic (GFAP) antigens sparsely 
revealed associations of neuropil vacuoles with these cell-types in either the KSS or the FL-
PGC-1α-deficient brains (Figure 16). Staining for MBP, however, unveiled that the vast 
majority of neuropil vacuoles were clearly encompassed by a myelin-positive rim, suggesting 
a same intramyelinic localization as for vacuoles within the WM (Figure 13B). Neuropil 
vacuoles were also frequently associated with oligodendrocytes in sections immunostained for 
TPPP/p25 (Figure 13C). Such close contacts of oligodendrocytes and vacuoles were also 
observed by electron microscopy. Furthermore, vacuoles (sometimes multiloculated) could 
frequently be identified within the cytoplasm of glial cells, which, due to the lack of glial fibers 
observed in the cytoplasm, also appeared to be oligodendrocytic (Figure 14C). Likewise myelin 
‘bubbles’, these membrane-bound vacuoles often contained myelin-like figures, and they 
occasionally coalesced occupying most of the oligodendroglial cytoplasm and led to the 
swelling of the cells (Figure 14C). These observations were seen in both the KSS and the FL-
PGC-1α-deficient brains. 
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Figure 13. Immunohistochemical characterization of vacuoles. Vacuoles within the WM 
are surrounded by rings of myelin (A; MBP). Likewise WM myelin ’bubbles’, vacuoles within 
the GM neuropil are also encompassed by a myelin-positive rim, suggesting an identical origin 
(B; MBP). Oligodendroglial cells in close contact with and/or localized within the inner edge 
of either single or multiloculated vacuoles can frequently be detected by immunohistochemistry 
(C; TPPP/p25), suggesting an important role of oligodendrocytes in vacuole formation. Note 
some of the larger vacuoles being separated to multiple chambers by oligodendroglial processes 
(C). Note also the glial cell encompassing a vacuole with its MBP+ process (indicated by 
arrows, A – left, B – right). Original publication in: [117]. 
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Figure 14. Ultrastructural characterization of vacuoles. Intramyelin vacuolation can be 
identified also by electron microscopy (longitudinal section, A; transverse section, B). In 
accordance with immunohistochemical findings, vacuoles, often multiloculated, can frequently 
be identified within the cytoplasm of oligodendroglial cells by electron microscopy (C). 
Oligodendroglial vacuoles have not been reported previously in mitochondrial 
encephalopathies, and their presence as a potential source of intramyelin vacuoles might 
underlie their focal appearance. Original publication in: [117]. 
 
34 
 
 
 
 
Figure 15. Distinct types of intramyelin vacuoles in KSS. Asterisk denotes a huge ’classical’ 
intramyelin vacuole originating from splitting at the intraperiod line. Arrows indicate the 
multiple presence of adaxonal vacuoles, some of which appear to originate from splitting 
between the two innermost myelin lamellae at higher power. The frequent appearance of 
adaxonal vacuoles may underpin the role of intraoligodendroglial vacuolar change in the 
development of intramyelin vacuoles in mitochondrial encephalopathies such as KSS, as 
discussed later. Original publication in: [117]. 
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Figure 16. Rare findings of vacuoles being in close contact with structures positive for 
staining against neuronal (A–B, MAP-2; C–D, SMI-32) or astroglial (E–F, GFAP) antigens. 
Notably, the vast majority of GM neuropil vacuoles have no immunohistochemically detectable 
association with such structures, which are often merely pushed by vacuoles of most probably 
distinct origin. Original publication in: [117]. 
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V. DISCUSSION 
The contribution of dysfunctional PGC-1α axis to the pathogenesis of mitochondrial 
dysfunction in neurodegenerative diseases is supported by the findings of an emerging number 
of experimental and human examinations. With multiple links associating PGC-1α dysfunction 
with neurodegenerative diseases, especially HD, PGC-1α-deficient mice with consistent early 
reports on striatal vacuolation and astrocytosis are frequently referred to as animals exhibiting 
HD-like pathology and phenotype. This was proposed to be in correspondence with hyperactive 
behavior of complete PGC-1α -/- mice, a finding that has, however, been contrasted by 
subsequent reports on various types of PGC-1α-deficient animals. Prompted by the facts that 
mitochondrial dysfunction and, though only at in vitro levels, PGC-1α deficiency has been 
causatively linked to pathological neuronal protein accumulation as a sign of impaired protein 
processing characteristic of neurodegenerative diseases, as well as by the notion that neither 
hyperactive behavior nor CNS vacuolation are typical features of mammalians with HD, our 
first pillar of investigations targeted at the lesion profiling of the brain of FL-PGC-1α -/- animals 
bred in our institute, with special focus on the accumulation of proteins associated with different 
neurodegenerative diseases. 
Indeed, based on evidences suggesting that mitochondrial dysfunction and impaired 
protein processing are interrelated, together with in vitro findings associating PGC-1α 
deficiency with protein accumulation [30, 55], we hypothesized that the ablation of FL-PGC-
1α could evoke the accumulation of neurodegeneration-related proteins in vivo. This concept 
seemed feasible as disturbances in protein processing and formation of aggregates have been 
demonstrated in rodents without a transgenic background for neurodegeneration-associated 
proteins (i.e., neurotoxin models [50, 118, 119] and aged animals [120]). However, our 
systematic immunohistochemical analysis revealed no protein depositions, with a complete lack 
of tangle-like structures, extracellular plaques, and ubiquitin-immunopositive inclusion bodies 
throughout the 30-weel-old murine brains, and the patterns of immunoreactivity were similar 
in FL-PGC-1α -/- and wild-type animals (Figure 7). Notably, the same set of 
immunohistochemical stainings performed on remarkably more aged, 70-75-week-old, FL-
PGC-1α -/- mice, revealed identical physiological patterns. These results indicate that despite 
its widely established contribution in neurodegenerative diseases, the absence of FL-PGC-1α 
has no major influence on protein processing in mice, suggesting a more complex scenario for 
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the interaction of mitochondrial dysfunction and protein aggregation in such conditions, and is 
consistent with the findings that neither the ablation [121] nor the overexpression [56] of PGC-
1α is associated with alterations in autophagy in nervous tissues. However, we cannot exclude 
the supplementary effect of NT-PGC1α254 in this context, which question could be answered 
by studying the complete PGC-1α -/- mice in a similar immunohistochemical paradigm. 
On the comprehensive neuropathological work-up, the observed alterations in FL-PGC-
1α -/- mice consisted of widespread spongiform vacuolation and circumscribed astrogliosis. 
The most striking spongiform alterations were observed in the long WM bundles of the internal 
capsule and the retroflex fascicle. The most severely affected GM regions included the thalamus 
and the caudate-putamen; however, basic myelin histology suggested the massive involvement 
of the pencil fibers streaming across the caudate-putamen, raising the possibility that the 
abundant vacuolation in this region is at least in part attributable to myelin degeneration. 
Notably, the whole forebrain, including the caudate-putamen, was free of gliosis, which 
contrasted with the robust and confluent astrogliotic reaction in the central pontomedullary 
brainstem, and the patchy reactions in the midbrain and the cerebellar nuclei. Collectively, this 
pattern is highly reminiscent of human mitochondrial spongiform encephalopathies, 
particularly of KSS and, in some aspects, LS (Table 2), but not of HD or any other ‘classical’ 
neurodegenerative disorders. This impression was further supported by the ovoid shape and 
unidirectional longitudinal axes of the vacuoles in the WM, the deep occipito-parietal 
preference of the cortical vacuoles, the median predominance of brainstem involvement, along 
with the seemingly preserved axons in the vacuolated fibers, all being typical features of 
mitochondrial status spongiosus. 
The relevance of the characterization of a viable animal model with mitochondrial 
encephalopathy is potentially striking, as the continuous attempts to create valid animal tools 
to model such diseases have been facing difficulties. Indeed, most of the developed genetic 
modifications resulted in embryonic or early postnatal lethality (e.g., knockouts of CREB [122], 
ERRγ [123], NRF-1 [124], NRF-2 [125], Tfam [126], mtDNA polymerase γ 1 (POLG1) [127], 
optic atrophy 1 (OPA1) [128] and synthesis of cytochrome c oxidase 2 (SCO2) [129]), whereas 
a great proportion of viable strains, surprisingly, exhibit no neuropathology (e.g., knockouts of 
ANT-1 [130], PPARγ [131], ERRα [132], and SURF1 [133]; Twinkle mutant ‘Deletor’ mice 
[134], and ΔmtDNA Mito-Mice [135]). To our knowledge, murine knockouts of AIF [136, 
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137], SOD2 [138], thymidine phosphorylase and uridine phosphorylase (TP/UP) [139], and 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 4 (NDUFS4) [140] are the only ones 
that display a neuropathology resembling that of human mitochondrial encephalopathies (Table 
2). Our finding that the anatomical pattern of the lesions in this model overlaps with multiple 
human mitochondrial encephalopathies is not that surprising, considering that FL-PGC-1α 
contributes to the proper functioning of several downstream proteins, which practically cover 
all levels of mitochondrial function that have been associated with mitochondrial diseases 
[100]. More surprisingly, PGC-1α-deficient mice are not only free of embryonic lethality, but 
have normal longevity and acceptable reproduction [111, 112], suggesting the existence of 
potent complementary pathways, probably within the PGC family itself. It is possible that the 
presence of intact PGC-1β and PGC-1-related coactivator (PRC) is sufficient to maintain an 
acceptable level of mitochondrial function, as both possess functional domains capable of 
interacting with nuclear hormone receptors and NRFs [141, 142]. Indeed, though PGC-1β 
expression was found unchanged in PGC-1α-deficient conditions [17, 111, 112, 143], the 
combined knockout mice of both PGC-1α and PGC-1β succumb to perinatal lethality due to 
heart failure [144]. 
Of note, the directly upstream CREB, and a number of downstream factors (ERRγ, 
NRF-1, NRF-2, Tfam, and POLG1) were found indispensable for embryonic or early postnatal 
development. On the other hand, the murine knockouts of the directly coactivated PPARγ and 
the PGC-1α-dependent ANT1 are viable, but display no neuropathological alterations. The 
most closely reminiscent brain pathology of that observed in this study was reported in the 
murine knockout of SOD2 (also acting downstream of PGC-1α), indicating that oxidative 
damage may play an important role in the development of the spongiform leukoencephalopathy. 
Although the lifespan of the SOD2 null model can be somewhat increased by antioxidant 
protection, these animals die within the first 3–4 weeks [138]. 
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Table 2. Comparative summary of the typical neuropathological findings and their 
distribution in human mitochondrial spongiform encephalopathies and their most 
reminiscent murine models. Original publication in: [115]. 
Disease Vacuolation  Anatomical 
predominance 
of vacuolation 
Astrogliosis Anatomical 
predominance 
of astrogliosis 
Reference 
Human disorders          
KSS + 
cerebral WM 
thalamus 
basal ganglia 
brainstem 
cerebellum 
+ 
brainstem 
cerebellum 
[101-104] 
LS + 
thalamus 
basal ganglia 
brainstem 
cerebellar nuclei 
+ 
thalamus 
basal ganglia 
brainstem 
cerebellar nuclei 
MELAS + 
cerebrum 
cerebellum 
+ 
cerebrum 
thalamus 
basal ganglia 
brainstem 
cerebellum 
MERRF + 
cerebrum 
brainstem 
+ 
basal ganglia 
brainstem 
cerebellar cortex 
cerebellar nuclei 
LHON + optic nerve + 
optic nerve 
retinal ganglia 
Experimental models        
FL-PGC-1α 
-/- mice 
+ 
cerebrum 
thalamus 
basal ganglia 
brainstem 
cerebellar nuclei 
+ 
brainstem 
cerebellar nuclei 
 
Ndufs4 -/- 
mice 
+ 
brainstem 
cerebellar nuclei 
+ 
brainstem 
cerebellar nuclei 
[140] 
TP/UP double 
-/- mice 
+ 
cerebral WM 
thalamus 
basal ganglia 
cerebellar WM 
cerebellar nuclei 
No data 
available 
 [139] 
SOD-2 -/- mice + 
cerebral cortex 
brainstem 
+ 
cerebral cortex 
brainstem 
[138] 
AIF -/- 
(Harlequin) 
mice 
-   + 
thalamus 
basal ganglia 
cerebellar nuclei 
retinal ganglia 
optic tract 
[136, 137] 
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The possibility that PGC-1α-deficient mice with their normal lifespan and some forms 
of measurable neurological deficits (though with contrasting reports) could represent a useful 
animal model to investigate these currently intractable group of diseases drove us to further 
characterize the neuropathological alterations of FL-PGC-1α -/- animals by a step-by-step 
comparison of aged 70-75-week-old mice and a human case of KSS, with special focus on the 
origin of vacuoles. 
Our immunohistochemical and ultrastructural analysis revealed that vacuolation in FL-
PGC-1α -/- mice is predominantly localized within the myelin sheath in the absence of 
morphological signs of axonal and scattered indications of astroglial or neuronal involvement. 
The findings were altogether strikingly similar to that seen in KSS, with a remarkable difference 
being that in KSS, the devastatingly vacuolated (cystic-necrotic) lesions presented also with 
myelin pallor and axonal disintegration. The sparing of axons in FL-PGC-1α -/- mice contrasts 
the concept proposed by Lin et al. during the initial characterization of the complete whole body 
PGC-1α -/- strain suggesting that the spongiform lesions in the caudate-putamen might arise 
from axonal degeneration [111], but corresponds with earlier findings on young (postnatal day 
10) FL-PGC-1α -/- animals using a semi-quantitative immunohistochemical assessment of 
striatal neurofilament-positive bundles [145]. Furthermore, the consistent lack of reactive 
astrocytes in this region even at an old age repeatedly questions the concept that PGC-1α-
deficient animals might indeed be models of HD. Notably, an independent group performing 
parallel examinations on the complete PGC-1α -/- strain recently reported no significant 
reduction in the number of MSNs in the knockout animals [146], supporting our observations. 
By contrast, during the preparation of our manuscript, the same group reported a significant 
loss of cerebellar Purkinje neurons in PGC-1α -/- mice by stereological methods [147], which 
is striking, as this feature is virtually pathognomonic of KSS. This observation independently 
(and unintentionally) confirms our concept. Unfortunately, we could not address this question 
due to technical issues. 
In addition to being the first side-by-side systematic comparison of human and animal 
mitochondrial encephalopathy to our knowledge published to date, this part of our study 
provided two main novelties. A first major finding of our study is that it demonstrates 
commonalities of vacuolation in the WM and GM, placing oligodendrocytes in the center of 
disease pathogenesis. Indeed, though the exact mechanism of vacuole formation in 
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mitochondrial encephalopathies has not yet been revealed, WM vacuoles are generally 
presumed to develop due to intramyelin edema secondary to mitochondrial dysfunction of 
oligodendrocytes, manifesting in splitting of the myelin sheath at the intraperiod line. On the 
other hand, GM neuropil vacuoles are presumed to develop due to ion transport disorder of 
astrocytic membranes [148-150]. Contrastingly, however, our observation that the vast majority 
of GM neuropil vacuoles are clearly myelin-bound in both the KSS and FL-PGC-1α-deficient 
brains indicates that the cellular localization and thus the mechanism of vacuole formation is 
most likely similar, irrespective of whether the vacuoles are in the WM or GM. This observation 
can explain the phenomenon widely observed in mitochondrial encephalopathies, including 
PGC-1α-deficient mice, that cortical vacuoles show a predilection toward the deeper layers of 
the neocortex, as the density of myelinated fibers apparently gradually decreases by 
approaching the superficial layers. Importantly, this could also explain the predilection of GM 
neuropil vacuoles toward the reticular area of the brainstem, thalamus, deep cerebellar nuclei, 
and basal ganglia adjacent to the internal capsule; as these GM regions are intermingled with 
the WM. Interestingly, these regions are the predilection areas for the development of GM 
vacuolation in hepatic encephalopathy as well [151]. Considering this overlapping predilection 
of spongy change between hepatic and mitochondrial encephalopathies, and that mitochondrial 
disorders, including PGC-1α deficiency [112], also commonly present with hepatic 
involvement, the contribution of liver insufficiency to the development of mitochondrial status 
spongiosus cannot be excluded either. Notably, intramyelin vacuolation has been frequently 
described in other experimental, veterinary and human metabolic conditions (Table 3), 
suggesting that this change might be a general response to various insults that compromise the 
metabolism of the myelin sheath and/or oligodendrocytes. 
As a second novelty, the ultrastructural analysis revealed the common appearance of 
intracellular, often multiloculated formation of vacuoles within oligodendroglial cells both in 
the KSS case and FL-PGC-1α-deficient brains. This finding was supported by the 
immunohistochemical observation of TPPP/p25-positive oligodendrocytes directly attaching to 
and sometimes bulging into vacuoles within the neuropil. The finding, however, that some 
vacuoles were observed closely attached to and partly encompassed by neuronal structures in 
MAP-2 and SMI-32 stainings suggests that at least a small proportion of neuropil vacuoles can 
be of neuronal origin, and that the mechanisms which lead to excessive intracellular membrane-
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bound fluid accumulation may affect different cell-types within the CNS, though to different 
extents. This hypothesis is supported by the report on CNS vacuoles observed also in neuron-
specific PGC-1α -/- mice [121]. 
Interestingly, though intracellular oligodendroglial vacuoles have not been previously 
described in mitochondrial diseases, their presence is not unprecedented in pathologies 
associated with mitochondrial dysfunction and/or severe cellular stress. Indeed, chronic feeding 
of mice with cuprizone, a copper-chelating mitochondrial toxin associated with 
megamitochondria [152] and alterations in complex IV and SOD activity [153], evokes a CNS 
pathology comprising vacuole formation in the pons, midbrain, thalamus, cerebral and 
cerebellar WM, as well as in deep cortical layers [154]. It was described that cuprizone-induced 
intramyelin vacuolation was due to splitting at the intraperiod line and was not stained by Sudan 
IV (equivalent with Oil Red O in our study) [154]. Additionally, the authors reported the 
presence of oligodendrocytes with enlarged cytoplasm containing multiloculated vesicles, and 
that some of these cells were juxtaposed to myelin sheaths, where a thin myelin layer appeared 
to form the glial membrane [154]. These findings are strikingly similar to those observed in our 
study. A further similarity between cuprizone-induced and mitochondrial status spongiosus is 
that cuprizone toxicity in doses evoking demyelination associates with oligodendroglial 
apoptosis [153], a phenomenon recently described in KSS [155]. Our observation of 
intraoligodendroglial vacuolation in mitochondrial encephalopathy expands the spectrum of 
disorders where this has been described (Table 4). 
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Table 3. Animal and human pathologies with intramyelin vacuolation. Original 
publication in: [117]. 
 
 
Experimental pathologies Reference 
Intoxication by  
actinomycin D [156] 
copper [157] 
cuprizone [154, 158] 
ethidium bromide [159] 
hexachlorophene [160] 
isonicotinic acid hydrazide [161] 
lysolecithin [162] 
triethyltin [163] 
Genetic models of   
mitochondrial dysfunction reviewed in [115] 
altered proteolipid expression [164] 
Models of scrapie 
[158, 165] 
Veterinary pathologies of various etiology   
Helichrysum poisoning in sheep and a goat 
Tetrapterys poisoning in sheep 
Maple syrup urine disease in calves 
Hereditary spongy degeneration of dogs 
Hereditary spongy degeneration of silver foxes 
[166] 
[167] 
[168] 
[169, 170] 
[171] 
Human pathologies  
Aging reviewed in [172] 
Aspartoacylase deficiency (Canavan’s disease) reviewed in [173] 
Hepatic encephalopathy reviewed in [173] 
Heroin-induced spongiform leukoencephalopathy [174] 
Maple syrup urine disease reviewed in [173] 
Mitochondrial disorders reviewed in [173] 
Urea cycle disorders reviewed in [173] 
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Table 4. Experimental and veterinary pathologies with previously reported 
oligodendroglial vacuolation. Original publication in: [117]. 
An interesting interrelation between mitochondrial leukoencephalopathies and multiple 
sclerosis (MS), a pathology where a potential central role of oligodendroglia is also suggested 
[116], is represented by the fact that the above mentioned cuprizone intoxication, presenting 
with a highly similar neuropathology to that observed in KSS and FL-PGC-1α-deficient mice 
in our study, is in fact a widely applied toxin model of MS [153, 181]. 
Besides dem3yelinating WM disease, our study also has implications for understanding 
WM lesions in the aging brain, a frequent pathology which includes the formation of 
intramyelin ‘balloons’ due to intraperiod line splitting [172], similar to that seen in 
mitochondrial disorders. Our observation that aged wild-type mice also developed vacuoles to 
an apparently slighter extent but at the same predilection areas as their FL-PGC-1α-deficient 
counterparts recapitulates previous observations [182]. Based on these, we propose that vacuole 
formation in mitochondrial encephalopathies and their representative animal models (e.g., 
PGC-1α-deficient mice) might also be regarded as an accelerated form of ‘normal’ WM 
degeneration, which underpins the role of (oligodendroglial) mitochondrial dysfunction in 
aging. 
Although the potential role of oligodendrocytes in WM vacuolation in mitochondrial 
encephalopathies has already been suggested, the fundamental concepts included 1) a disrupted 
ion-homeostasis of the sheath, 2) a dysfunction of the blood-brain barrier, in both cases with 
consequent development of ‘intramyelin edema’ [148-150]. These hypotheses, however, do not 
explain why vacuoles develop focally and how multiple vacuoles can be found within the same 
Experimental and pathologies Reference 
Cuprizone intoxication [154] 
Ionizing radiation [175] 
Methionine sulfoximine intoxication [176] 
Triethyltin intoxication in quaking mice [177] 
Twitcher mouse [178] 
Zitter rat [179] 
Veterinary pathologies  
Hereditary ataxia of the rabbit [180] 
Hereditary spongy degeneration of silver foxes [171] 
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internode, instead of a complete splitting and diffuse loosening of the sheath between all 
lamellae. We propose that chronic mitochondrial dysfunction in a yet unknown pathway leads 
to the formation of multiple intraoligodendroglial fluid-filled vacuoles. The increased 
intracellular content might provoke splitting between the intracellular surfaces of the myelin 
sheath (major dense line). Due to their firm connections at the macromolecular level, this would 
cause tears and focal myelin disruptions, allowing the vacuolar content to access into the virtual 
space between the loosely attached extracellular surfaces (intraperiod lines). Consequently, this 
could evoke the formation of focal splits and eventually myelin bubbles. Accordingly, 
disruption of the lateral loops or probably of developmental remnants of the cytoplasmic 
incisures would result in intraperiod line splitting at the corresponding levels, whereas leakage 
from the inner tongue would cause adaxonal swelling between the axolemma and the innermost 
myelin lamellae or between the two innermost layers. Supporting this theoretical consideration, 
such distinct types of intramyelin vacuoles have indeed been described in experimental status 
spongiosus [156, 159], and could also be observed in our study (Figure 15). 
Our observations, therefore, place oligodendrocytes in the center of the pathogenesis of 
CNS lesioning in association with chronic mitochondrial dysfunction in both the WM and GM, 
which is in line with the recognition that oligodendrocytes, contrasting with astrocytes [21], are 
most sensitive to mitochondrial stress, exceeding the vulnerability of neurons [22]. This may 
serve as rationale for cytoprotective targeting of oligodendrocytes in mitochondrial 
encephalopathies as well as in other disorders with vacuole formation and myelin degeneration. 
VI. CONCLUSION 
In our studies, we systematically characterized the neuropathological alterations of a 
murine strain deficient in the expression of full-length PGC-1α protein, a mitochondrial master 
regulator of biogenesis, respiration, and antioxidant responses. Providing multiple lines of 
evidence that this animal strain does not associate with morphological features of 
neurodegenerative diseases, including HD, we reported the characterization of a phenotype 
strikingly reminiscent of that seen in mitochondrial encephalopathies, especially in KSS. 
Extending our investigations to further immunohistochemical and ultrastructural levels on a 
systematic comparison with the human disease, we identified novel pathological alterations 
present in both human KSS and FL-PGC-1α -/- animals, providing basis of a novel generalized 
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theory for vacuole formation in mitochondrial and probably other metabolic diseases. We 
propose that PGC-1α-deficient mice can be an appropriate animal model for this yet incurable 
group of diseases, and should be subjected to examination with therapeutic aim. 
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